JMP Securities analyst Reni Benjamin lowered the firm’s price target on Bicycle Therapeutics (BCYC) to $26 from $32 and keeps an Outperform rating on the shares. The firm is pushing back its estimated launch of zelenectide pevedotin to 1Q28 from 1Q27 given the current enrollment pace, the analyst tells investors in a research note. JMP continues to believe Bicycle shares represent a unique investment opportunity, especially after the recent selloff, with the zele pivotal trial enrolling, two additional assets advancing through the clinic, multiple partnerships providing non-dilutive capital and external pipeline validation, and a strong cash position of $890.9M.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCYC:
- Biotech Alert: Searches spiking for these stocks today
- Bicycle Therapeutics price target lowered to $33 from $55 at H.C. Wainwright
- Bicycle Therapeutics price target lowered to $17 from $28 at B. Riley
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call